A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- 10 Aug 2017 According to a Syndax Pharmaceuticals media release, as of the end of July, the trial was 78% enrolled.
- 10 Jun 2017 Biomarkers information updated
- 08 May 2017 According to a Syndax Pharmaceuticals media release, completion of enrollment and progression free survival analysis are anticipated in the first half of 2018.